Cargando…

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence

Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis. Terlipressin has not been considered as the mainstay treatment option for ascites in cirrhosis yet. The presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Zhaohui, An, Yang, Guo, Xiaozhong, Teschke, Rolf, Méndez-Sánchez, Nahum, Li, Hongyu, Qi, Xingshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333040/ https://www.ncbi.nlm.nih.gov/pubmed/32676484 http://dx.doi.org/10.1155/2020/5106958

Ejemplares similares

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding
por: Zhang, Jingqiao, et al.
Publicado: (2020)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty
por: Qi, Xingshun, et al.
Publicado: (2016)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Successful Pharmacotherapy for Multiple Acute Decompensation Events in a Cirrhotic Patient with Acute-on-chronic Liver Failure: A Case Report
por: Xu, Xiangbo, et al.
Publicado: (2018)

Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis
por: Wu, Yanyan, et al.
Publicado: (2020)

Prognostic Markers in Patients with Ascites and Hepatorenal Syndrome
por: Nazal, Leyla, et al.
Publicado: (2011)

Current approaches to the management of patients with cirrhotic ascites
por: Garbuzenko, Dmitry Victorovich, et al.
Publicado: (2019)

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
por: Curry, Michael P., et al.
Publicado: (2023)

Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence
por: Xu, Xiangbo, et al.
Publicado: (2019)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?
por: Bai, Zhaohui, et al.
Publicado: (2021)

Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis
por: Li, Hongyu, et al.
Publicado: (2018)

Is the use of non-selective beta-blockers necessary in cirrhotic patients with small varices?
por: Qi, Xingshun, et al.
Publicado: (2014)

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2019)

Practice guidance for the use of terlipressin for liver cirrhosis–related complications
por: Qi, Xingshun, et al.
Publicado: (2022)

Renal blood flow in cirrhotic patients and hepatorenal syndrome (HRS)
por: Nagi, HK, et al.
Publicado: (2002)

Hepatorenal Syndrome with Cirrhotic Cardiomyopathy: Case Report and Literature Review
por: Mocarzel, Luis, et al.
Publicado: (2015)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

No Mortality Difference Following Treatment with Terlipressin or Somatostatin in Cirrhotic Patients with Gastric Variceal Hemorrhage
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis
por: Li, Jing, et al.
Publicado: (2018)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0k93jv5mtp4c4p13kfhrd3e617